$1.1 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
-Total revenue in the last quarter.
$-62.9 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
$-4.73Earnings per share is the amount of net income that is attributed to each single share outstanding.
-Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
-3.64xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$-72.2 MillionEarnings before interest expenses and taxes in the last quarter.
316The number of full time employees.
Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of org...PR Newswire, 10 days ago
DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ending September 30, ...PR Newswire, 21 days ago
Theravance Biopharma Inc (NASDAQ:TBPH) traded up 5.3% during mid-day trading on Thursday . The company traded as high as $19.13 and last traded at $19.03. 258,232 shares were traded during mid-day ...The Olympia Report, about 1 month ago